Abstracts tagged "Antiphospholipid syndrome and thrombosis"

Abstract Number: 167 • 2018 ACR/ARHP Annual Meeting
Recurrent Thrombosis in Patients with Antiphospholipid Antibodies Following an Initial Venous or Arterial Thromboembolic Event
Tom Ortel¹, Sreelatha Meleth², Diane Catellier², Mark Crowther³, Doruk Erkan⁴, Paul R. Fortin⁵, David Garcia⁶, Nana Haywood², Steven R. Levine⁷, Michael J. Phillips² and Nedra Whitehead², ¹Duke University, Durham, NC, ²RTI International, Research, Triangle Park, NC, ³McMaster University, Hamilton, ON, Canada, ⁴Rheumatology, Hospital for Special Surgery- Weill Cornell Medicine, New York, NY, ⁵Medicine, CHU de Québec - University of Laval, Quebec, QC, Canada, ⁶Hematology, University of Washington Medical Center, Seattle, WA, ⁷Neurology, State University of New York Downstate Medical Center, Brooklyn, NY
Background/Purpose: After an initial thromboembolic event (TE), several studies reported that patients with antiphospholipid syndrome (APS) manifest a high-risk for recurrent TE. A systematic review…
Abstract Number: 10 • 2017 ACR/ARHP Annual Meeting
Arterial Events in Primary Antiphospholipid Syndrome Are Associated with High Values of the Adjusted Global Antiphospholipid Syndrome Score
Flavio Signorelli¹, Gustavo G M Balbi², Roger A. Levy² and Savino Sciascia³, ¹Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ²Rheumatology, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ³Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy
Background/Purpose: The adjusted Global AntiPhospholipid Syndrome Score (aGAPSS) was described as a tool to estimate the risk of thromboses in patients with APS. The aim…
Abstract Number: 16 • 2017 ACR/ARHP Annual Meeting
Anti-Phosphatidylserine/Prothrombin Antibodies in Primary Antiphospholipid Syndrome
Paola Bermudez-Bermejo¹, Gabriela Hernandez-Molina², Diego Hernández-Ramírez³, Victor Zamora-Legoff², Elizabeth Olivares-Martínez³, Antonio R. Cabral⁴ and Carlos Núñez-Álvarez⁵, ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion SZ, Mexico City, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición SZ, mexico city, Mexico, ³Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ⁴Department of Medicine. Division of Rheumatology, The Ottawa Hospital.University of Ottawa, Ottawa, ON, Canada, ⁵Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion S.Z., Mexico city, Mexico
Background/Purpose: Several studies have showed conflicting results regarding the presence and meaning of anti-phosphatidylserine/prothrombin (aPS/PT). However aPS/PT antibodies seem to be a risk factor for…
Abstract Number: 3 • 2017 ACR/ARHP Annual Meeting
Burden of Antiphospholipid Syndrome in a Thromboembolic Disease Registry
Aurelia Luissi¹, Marina Scolnik¹, Maria Florencia Grande Ratti², Maria Lourdes Posadas Martinez² and Enrique R. Soriano³, ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, CABA, Argentina, ²Research Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, CABA, Argentina, ³Rheumatology Unit, Internal Mecine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Background/Purpose: Prevalence of antiphospholipid antibodies in general population has been reported in about 5%. Impact of different thrombophilias in clinical thromboembolic disease is difficult to…
Abstract Number: 7 • 2017 ACR/ARHP Annual Meeting
Predictive Value for Thrombosis of Double or Triple Positivity in Secondary APS Depends on the Component Assays and the Type of Thrombosis
Michelle Petri¹, Daniel Goldman² and Laurence S Magder³, ¹Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Epidemiology and Public health, University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: The lupus anticoagulant (LAC) is individually the antiphospholipid antibody (aPL) most associated with thrombotic risk in both primary and secondary APS. Anticardiolipin (aCL) and…
Abstract Number: 1064 • 2016 ACR/ARHP Annual Meeting
Antiphospholipid Syndrome Alliance for Clinical Trials & International Networking Registry Analysis: Direct Oral Anticoagulant Use Among Antiphospholipid Syndrome Patients
Ozan Unlu¹, Hannah Cohen², Maria Jose Cuadrado³, Paul R. Fortin⁴, Guilherme Ramires de Jesus⁵, Maria Gerosa⁶, Jason K Knight⁷, Vittorio Pengo⁸, Michelle Petri⁹, Esther Rodriguez-Almaraz¹⁰, Stephane Zuily^11,12, Doruk Erkan¹³ and On Behalf of APS ACTION .¹⁴, ¹Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ²University College London, London, United Kingdom, ³Lupus Research Unit, The Rayne Institute, St Thomas' Hospital, London, United Kingdom, ⁴Medicine, CHU de Québec - Université Laval, Québec, QC, Canada, ⁵Department of Obstetrics, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ⁶University of Milan, Istituto Ortopedico Gaetano Pini, Milano, Italy, ⁷University of Michigan, Ann Arbor, MI, ⁸Azienda Ospedaliera of Padova, University of Padova, Padova, Italy, ⁹Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁰Servicio De Reumatología, Hospital 12 De Octubre,, Madrid, Spain, ¹¹CHU de Nancy, Regional Competence Centre For Rare Vascular And Systemic Autoimmune Diseases, Vascular Medicine Division, NANCY, France, ¹²Inserm, UMR_S 1116, Nancy, France, ¹³Rheumatology, Hospital for Special Surgery- Weill Cornell Medicine, New York, NY, ¹⁴., New York, NY
Background/Purpose: Direct oral anticoagulants (DOACs) are approved for the treatment of venous, and prevention of venous/arterial thrombosis. There have been case reports/ series where DOACs…
Abstract Number: 2093 • 2016 ACR/ARHP Annual Meeting
Association of Conventional Risk Factors and Antiphospholipid Antibodies to Thrombosis in Patients with Autoimmune Diseases: Lessons Learned from a Year-Long Systematic Assessment
Polona Žigon¹, Anuška Podovšovnik², Ales Ambrozic³, Matija Tomsic¹, Alojzija Hocevar¹, Natasa Gaspersic³, Ziga Rotar¹, Sonja Praprotnik⁴, Snezna Sodin Semrl^1,5 and Saša Čučnik^1,6, ¹Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ²Divison of Internal Medicine, General Hospital Izola, Izola, Slovenia, ³Department of Rheumatology, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia, ⁴Department of Rheumatology, University Medical Centre Ljubljana, Slovenia, Ljubljana, Slovenia, ⁵Faculty of Mathematics, Natural Science and Information Technology, University of Primorska, Koper, Slovenia, ⁶Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia
Background/Purpose: Patients with autoimmune disorders are at risk for thrombotic events and antiphospholipid antibodies (aPL) are one of known markers of increased thrombotic risk. The…
Abstract Number: 2096 • 2016 ACR/ARHP Annual Meeting
Venous Antiphospholipid Syndrome: Is the Unprovoked Nature of the 1st Thrombosis Associated with Clinical or Biological Features?
Marc Lambert¹, Mohamed-Amine Oukili², Cécile Yelnik³, Eric Hachulla¹, Pierre-Yves Hatron¹, Mehdi Djennaoui⁴ and Thomas Quémeneur², ¹CHU Lille, Département de Médecine Interne et Immunologie Clinique, F-59000 Lille, France, Lille, France, ²Service de néphrologie, médecine interne et vasculaire, Hôpital de Valenciennes, Valenciennes, France, ³Service de médecine interne, centre de référence des maladies systémiques et auto-immunes rares, Hôpital Claude Huriez, CHRU Lille, Lille, France, ⁴Unité de biostatistiques, Hôpital de Valenciennes, Valenciennes, France
Background/Purpose: Risk of recurrence after a first episode of venous thrombo-embolism (VTE) is strongly correlated to VTE characteristics. Indefinite anticoagulation is recommended for patients with…
Abstract Number: 2002 • 2015 ACR/ARHP Annual Meeting
Dnase Treatment Protects Against DVT Formation in a Mouse Model of Antiphospholipid Syndrome
He Meng¹, Srilakshmi Yalavarthi², Levi F. Mazza³, Megan A. Elfline¹, Catherine E. Luke¹, Peter K. Henke¹ and Jason S. Knight², ¹University of Michigan, Ann Arbor, MI, ²Division of Rheumatology, University of Michigan, Ann Arbor, MI, ³Department of Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Antiphospholipid antibodies, especially those targeting beta-2-glycoprotein I (β2GPI), have been shown to amplify thrombosis in mice. However, most published models have relied on endothelial…
Abstract Number: 2864 • 2014 ACR/ARHP Annual Meeting
Markers of Thrombotic Events in Autoimmune Diseases:Comparison of Antiphospholipid Score (aPL-S) and Global Anti-Phospholipid Syndrome Score (GAPSS)
Kenji Oku, Olga Amengual, Ryo Hisada, Kazumasa Oomura, Ikuma Nakagawa, Toshiyuki Watanabe, Toshiyuki Bohgaki, Tetsuya Horita, Shinsuke Yasuda and Tatsuya Atsumi, Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
Background/Purpose Recently, new scoring systems to quantify the probability for the diagnosis of antiphospholipid syndrome (APS) have been proposed in sequence: the Antiphospholipid Score(aPL-S) and…
Abstract Number: 11 • 2014 ACR/ARHP Annual Meeting
Sustained Moderate Intensity Levels of Oral Anticoagulant Therapy and the Rate of Recurrent Thrombosis in Patients with Primary Antiphospholipid Syndrome
Alonso Turrent¹, Gabriela Hernandez-Molina² and Antonio R. Cabral³, ¹Immunology and Rheumatology, Instituto Nacional De Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, ³Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico
Background/Purpose: The current recommended anti-thrombotic therapy for patients with anti-phospholipid syndrome (APS) is oral anticoagulants with an INR intensity between 2-3. This recommendation has been…
Abstract Number: 19 • 2013 ACR/ARHP Annual Meeting
Association Of Antiphospholipid Antibodied Detected In The Aphl ELISA With Clinical Manifestations Of The Antiphospholipid Syndrome In Two Lupus Cohorts
Silvia S. Pierangeli¹, Rohan Willis², Michelle Petri³, Hong Fang⁴, Monica Smikle⁵, Karel de Ceulaer⁶ and E. Nigel Harris⁷, ¹Rheumatology/Dept Int Med, University of Texas Medical Branch, Galveston, TX, ²Int Medicine/Rheumatology, University of Texas Medical Branch, Galveston, TX, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Microbiology, University of the West Indies, Kgn 7, Jamaica, ⁶Microbiology, University of the West Indies, KIngston, Jamaica, ⁷Office of the Vice Chancellor, The University of the West Ind, Kingston, Jamaica
Background/Purpose: Antiphospholipid Syndrome (APS) is characterized by the presence of antibodies to phospholipid (aPL) and to β2glycoprotein I (β2GPI) in patients with thrombosis or pregnancy…
Abstract Number: 3 • 2013 ACR/ARHP Annual Meeting
The Global Antiphospholipid Syndrome Score (GAPSS) In Primary APS
Savino Sciascia¹, Giovanni Sanna², Veronica Murru³, Dario Roccatello¹, Munther A. Khamashta⁴ and Maria Laura Bertolaccini³, ¹Department of Rare, Immunologic, Hematologic and Immunohematologic Diseases, Centro di Immunopatologia e Documentazione su Malattie rare, Torino, Italy, ²Louise Coote Lupus Unit, St. Thomas' Hospital, London, United Kingdom, ³Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, ⁴Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom
Background/Purpose: Antiphospholipid Syndrome (APS) is a heterogeneous entity with a wide variation in clinical course and laboratory profile. We aimed to evaluate the clinical utility…
Abstract Number: 1727 • 2012 ACR/ARHP Annual Meeting
Affinity Purified Antibodies Directed to Domain I of β2GPI Are Pathogenic in a Mouse Model of Thrombosis
Charis Pericleous¹, Patricia Ruiz-Limon², Zurina Romay-Penabad², Ana Laura Carrera Marin², Acely Garza-Garcia³, Lucy Murfitt³, Paul C. Driscoll⁴, Ian Giles⁵, Yiannis Ioannou⁶, Anisur Rahman⁵ and Silvia S. Pierangeli², ¹Centre for Rheumatology, Division of Medicine, Centre for Rheumatology, University College London, London, United Kingdom, ²Rheumatology/Dept Int Med, University of Texas Medical Branch, Galveston, TX, ³Molecular Structure, MRC National Institute of Medical Research, London, London, United Kingdom, ⁴Molecular Structure, MRC National Institute of Medical Research, London, United Kingdom, ⁵Centre for Rheumatology Research,Rayne Institute, 4th Floor, University College London, London, United Kingdom, ⁶Arthritis Research UK Centre for Adolescent Rheumatology at University College London, Great Ormond Street Hospital and UCLH, University College London, London, United Kingdom
Background/Purpose: Circulating IgG antiphospholipid antibodies (aPL) against β2-glycoprotein I (aβ2GPI) are a serological hallmark for diagnosis of the antiphospholipid syndrome (APS). We and other groups…
Abstract Number: 1731 • 2012 ACR/ARHP Annual Meeting
IgA Anti-β₂glycoprotein I Antibodies Are Pathogenic in a Mouse Model of APS
Patricia Ruiz Limon¹, Zurina Romay-Penabad², Ana Laura Carrera Marin³, Elizabeth Papalardo⁴ and Silvia S. Pierangeli³, ¹Rheumatolgoy/Dept Int Med, University of Texas Medical Branch, Galveston, TX, ²Rheumatology/Dept Int Med, Univ of TX Medical Branch, Galveston, TX, ³Rheumatology/Dept Int Med, University of Texas Medical Branch, Galveston, TX, ⁴Louisville APL Diagnostics, Inc, Seabrook, TX
Background/Purpose: Recently exclusive IgA anti-b2Glycoprotein I (ab2GPI) seropositivity - in the absence of any other antiphospholipid (aPL) antibodies- has been reported particularly in SLE patients. …

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].